Bingham Private Wealth LLC Sells 547 Shares of Pfizer Inc. $PFE

Bingham Private Wealth LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,152 shares of the biopharmaceutical company’s stock after selling 547 shares during the quarter. Bingham Private Wealth LLC’s holdings in Pfizer were worth $343,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the first quarter worth $27,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the first quarter worth $28,000. North Capital Inc. bought a new stake in shares of Pfizer during the first quarter worth $28,000. WPG Advisers LLC bought a new stake in shares of Pfizer during the first quarter worth $35,000. Finally, Horizon Financial Services LLC bought a new stake in shares of Pfizer in the first quarter valued at about $35,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. UBS Group restated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.41.

Pfizer Price Performance

PFE opened at $26.45 on Tuesday. The business’s 50-day moving average is $24.72 and its two-hundred day moving average is $24.12. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market capitalization of $150.38 billion, a PE ratio of 14.07, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm earned $0.60 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.